-
Posted by
Two Blokes Jun 29 -
Filed in
Stock
-
5 views
Ionis is transitioning from a licensing model to a commercial-stage biotech, investing heavily in its own drug launches and development pipeline. Upcoming catalysts include donidalorsen's FDA decision and olezarsen's Phase 3 data, both with significant peak sales potential in underserved markets. Despite ongoing losses and commercial execution risks, Ionis' validated platform and differentiated drugs offer compelling long-term growth opportunities.
